{"id":1838,"date":"2014-05-08T00:00:00","date_gmt":"2014-05-08T00:00:00","guid":{"rendered":"http:\/\/www.neurodegenerationresearch.eu\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/"},"modified":"2014-09-22T09:14:38","modified_gmt":"2014-09-22T09:14:38","slug":"exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease","status":"publish","type":"post","link":"https:\/\/neurodegenerationresearch.eu\/it\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/","title":{"rendered":"Exenatide has potential as a disease modifying agent in Parkinson&#8217;s disease"},"content":{"rendered":"<p><strong>A glucagon-like peptide-1 agonist (GLP-1 agonist) medication, Exenatide, marketed as Byetta\u00ae and Bydureon\u00ae is used in the treatment of insulin resistance in patients with Type 2 diabetes. <\/strong><\/p>\n<p>Several recent discoveries have highlighted common cellular pathways that potentially relate neurodegenerative processes with abnormal mitochondrial function and abnormal glucose metabolism. <\/p>\n<p>A follow-up study of patients with Parkinson&#8217;s disease (PD) who participated in an earlier &amp;quot;proof of concept&amp;quot; clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the <link http:\/\/www.journalofparkinsonsdisease.com\/JPD\/Home_files\/JPD%20Exenatide%20Has%20Potential%20as%20a%20Disease%20Modifying%20Agent%20.pdf - external-link-new-window \"Opens external link in new window\">Journal of Parkinson&#8217;s Disease<\/link>. <\/p>\n<p>Earlier studies had shown that exenatide is neuroprotective and promotes functionally beneficial neuroplasticity in animal models of neurodegeneration. Furthermore, exenatide has a favorable safety profile, with only relatively mild gastrointestinal side effects (including nausea and weight loss) as frequent adverse events. <\/p>\n<p>In an earlier &amp;quot;proof of concept&amp;quot; randomized controlled trial published in May 2013, participants were randomized to either self-administer exenatide in addition to their regular PD medications or to act as controls, i.e., receive their conventional PD treatment only. All of the participants had moderate severity PD. In total, 44 patients (20 in the exenatide group and 24 controls) completed the trial. After 12 months the results showed significant and clinically meaningful differences in both motor and cognitive symptoms between those patients receiving exenatide and the controls. At 14 months, when the patients had discontinued exenatide for two months, the exenatide-treated and control groups still differed from each other. The authors concluded that the study supported potential disease-modifying benefits of exenatide in PD, while acknowledging the lack of a placebo arm. <\/p>\n<p>Source: Science Codex<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A glucagon-like peptide-1 agonist (GLP-1 agonist) medication, Exenatide, marketed as [&hellip;]<\/p>\n<a href=\"https:\/\/neurodegenerationresearch.eu\/it\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/\">View Post<\/a>","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[22],"tags":[],"class_list":["post-1838","post","type-post","status-publish","format-standard","hentry","category-research-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Exenatide has potential as a disease modifying agent in Parkinson&#039;s disease - JPND Neurodegenerative Disease Research<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/\" \/>\n<meta property=\"og:locale\" content=\"it_IT\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exenatide has potential as a disease modifying agent in Parkinson&#039;s disease - JPND Neurodegenerative Disease Research\" \/>\n<meta property=\"og:description\" content=\"A glucagon-like peptide-1 agonist (GLP-1 agonist) medication, Exenatide, marketed as [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/\" \/>\n<meta property=\"og:site_name\" content=\"JPND Neurodegenerative Disease Research\" \/>\n<meta property=\"article:published_time\" content=\"2014-05-08T00:00:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2014-09-22T09:14:38+00:00\" \/>\n<meta name=\"author\" content=\"jpnd\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@JPNDeurope\" \/>\n<meta name=\"twitter:site\" content=\"@JPNDeurope\" \/>\n<meta name=\"twitter:label1\" content=\"Scritto da\" \/>\n\t<meta name=\"twitter:data1\" content=\"jpnd\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tempo di lettura stimato\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/\"},\"author\":{\"name\":\"jpnd\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/person\\\/a97e49cae588ead81db59e48a4e63c2a\"},\"headline\":\"Exenatide has potential as a disease modifying agent in Parkinson&#8217;s disease\",\"datePublished\":\"2014-05-08T00:00:00+00:00\",\"dateModified\":\"2014-09-22T09:14:38+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/\"},\"wordCount\":291,\"publisher\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\"},\"articleSection\":[\"Research News (General)\"],\"inLanguage\":\"it-IT\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/\",\"name\":\"Exenatide has potential as a disease modifying agent in Parkinson's disease - JPND Neurodegenerative Disease Research\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#website\"},\"datePublished\":\"2014-05-08T00:00:00+00:00\",\"dateModified\":\"2014-09-22T09:14:38+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/#breadcrumb\"},\"inLanguage\":\"it-IT\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/tr\\\/2014\\\/05\\\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exenatide has potential as a disease modifying agent in Parkinson&#8217;s disease\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#website\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\",\"name\":\"JPND Neurodegenerative Disease Research\",\"description\":\"Neurodegenerative Disease Research\",\"publisher\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"it-IT\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#organization\",\"name\":\"JPND\",\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.neurodegenerationresearch.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/logo.png\",\"contentUrl\":\"https:\\\/\\\/www.neurodegenerationresearch.eu\\\/wp-content\\\/uploads\\\/2022\\\/03\\\/logo.png\",\"width\":248,\"height\":129,\"caption\":\"JPND\"},\"image\":{\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/JPNDeurope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/#\\\/schema\\\/person\\\/a97e49cae588ead81db59e48a4e63c2a\",\"name\":\"jpnd\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"it-IT\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g\",\"caption\":\"jpnd\"},\"url\":\"https:\\\/\\\/neurodegenerationresearch.eu\\\/it\\\/author\\\/jpnd\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exenatide has potential as a disease modifying agent in Parkinson's disease - JPND Neurodegenerative Disease Research","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/","og_locale":"it_IT","og_type":"article","og_title":"Exenatide has potential as a disease modifying agent in Parkinson's disease - JPND Neurodegenerative Disease Research","og_description":"A glucagon-like peptide-1 agonist (GLP-1 agonist) medication, Exenatide, marketed as [&hellip;]","og_url":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/","og_site_name":"JPND Neurodegenerative Disease Research","article_published_time":"2014-05-08T00:00:00+00:00","article_modified_time":"2014-09-22T09:14:38+00:00","author":"jpnd","twitter_card":"summary_large_image","twitter_creator":"@JPNDeurope","twitter_site":"@JPNDeurope","twitter_misc":{"Scritto da":"jpnd","Tempo di lettura stimato":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/#article","isPartOf":{"@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/"},"author":{"name":"jpnd","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/person\/a97e49cae588ead81db59e48a4e63c2a"},"headline":"Exenatide has potential as a disease modifying agent in Parkinson&#8217;s disease","datePublished":"2014-05-08T00:00:00+00:00","dateModified":"2014-09-22T09:14:38+00:00","mainEntityOfPage":{"@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/"},"wordCount":291,"publisher":{"@id":"https:\/\/neurodegenerationresearch.eu\/#organization"},"articleSection":["Research News (General)"],"inLanguage":"it-IT"},{"@type":"WebPage","@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/","url":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/","name":"Exenatide has potential as a disease modifying agent in Parkinson's disease - JPND Neurodegenerative Disease Research","isPartOf":{"@id":"https:\/\/neurodegenerationresearch.eu\/#website"},"datePublished":"2014-05-08T00:00:00+00:00","dateModified":"2014-09-22T09:14:38+00:00","breadcrumb":{"@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/#breadcrumb"},"inLanguage":"it-IT","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neurodegenerationresearch.eu\/tr\/2014\/05\/exenatide-has-potential-as-a-disease-modifying-agent-in-parkinsons-disease\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neurodegenerationresearch.eu\/"},{"@type":"ListItem","position":2,"name":"Exenatide has potential as a disease modifying agent in Parkinson&#8217;s disease"}]},{"@type":"WebSite","@id":"https:\/\/neurodegenerationresearch.eu\/#website","url":"https:\/\/neurodegenerationresearch.eu\/","name":"JPND Neurodegenerative Disease Research","description":"Neurodegenerative Disease Research","publisher":{"@id":"https:\/\/neurodegenerationresearch.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neurodegenerationresearch.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"it-IT"},{"@type":"Organization","@id":"https:\/\/neurodegenerationresearch.eu\/#organization","name":"JPND","url":"https:\/\/neurodegenerationresearch.eu\/","logo":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.neurodegenerationresearch.eu\/wp-content\/uploads\/2022\/03\/logo.png","contentUrl":"https:\/\/www.neurodegenerationresearch.eu\/wp-content\/uploads\/2022\/03\/logo.png","width":248,"height":129,"caption":"JPND"},"image":{"@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/JPNDeurope"]},{"@type":"Person","@id":"https:\/\/neurodegenerationresearch.eu\/#\/schema\/person\/a97e49cae588ead81db59e48a4e63c2a","name":"jpnd","image":{"@type":"ImageObject","inLanguage":"it-IT","@id":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b3244fc6099279fad29cb751cb709c5ee57befcda19ef0b44a4f0067989d7f7e?s=96&d=mm&r=g","caption":"jpnd"},"url":"https:\/\/neurodegenerationresearch.eu\/it\/author\/jpnd\/"}]}},"_links":{"self":[{"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/posts\/1838","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/comments?post=1838"}],"version-history":[{"count":0,"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/posts\/1838\/revisions"}],"wp:attachment":[{"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/media?parent=1838"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/categories?post=1838"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/neurodegenerationresearch.eu\/it\/wp-json\/wp\/v2\/tags?post=1838"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}